Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | DDO | Q99489 | 1/20 | 0.69 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033490 | 1.00 | KDM4E (0.69) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL9448500 | 0.98 | KDM4E (0.67) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL2841794 | 0.85 | SIRT2 (0.54) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL27750302 | 0.84 | KDM4E (0.72) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL29954828 | 0.82 | ALDH1A1 (1.00) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL185913 | 0.82 | ALDH1A1 (1.00) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL3044926 | 0.80 | KDM4E (0.67) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL9448329 | 0.80 | ALDH1A1 (0.96) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL6754398 | 0.79 | MKNK1 (0.67) | SIRT2SIRT1SIRT3F7F3 | |
| SCHEMBL2645556 | 0.77 | SIRT2 (0.47) | KDM4EMEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5215738-A | Used for destroying hypoxic tumor cells | SRI INTERNATIONAL (US) | 1993-06-01 | — | — | US | claimed |
| WO-1986006628-A1 | BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS | SRI INTERNATIONAL (US) | 1986-11-20 | — | — | WO | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-0855909-A1 | RADIOSENSITIZING TAXANES AND THEIR PHARMACEUTICAL PREPARATIONS | FLORIDA STATE UNIVERSITY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1998014190-A9 | PHARMACEUTICAL COMPOUNDS COMPRISING POLYAMINES SUBSTITUTED WITH ELECTRON-AFFINIC GROUPS | — | 1998-07-30 | — | — | WO | disclosed |
| WO-1998014190-A1 | PHARMACEUTICAL COMPOUNDS COMPRISING POLYAMINES SUBSTITUTED WITH ELECTRON-AFFINIC GROUPS | FLORIDA STATE UNIVERSITY (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997009979-A9 | RADIOSENSITIZING TAXANES AND THEIR PHARMACEUTICAL PREPARATIONS | — | 1997-06-05 | — | — | WO | disclosed |
| WO-1997009979-A1 | RADIOSENSITIZING TAXANES AND THEIR PHARMACEUTICAL PREPARATIONS | FLORIDA STATE UNIVERSITY (US) | 1997-03-20 | — | — | WO | disclosed |
| US-5215738-A | Used for destroying hypoxic tumor cells | SRI INTERNATIONAL (US) | 1993-06-01 | — | — | US | disclosed |
| US-5215738-A | Used for destroying hypoxic tumor cells | SRI INTERNATIONAL (US) | 1993-06-01 | — | — | US | disclosed |
| US-4647569-A | Antiarthritic pyridylaminoethene disulfonyl compounds and use | MAY & BAKER LIMITED (GB) | 1987-03-03 | — | — | US | disclosed |
| WO-1986006628-A1 | BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS | SRI INTERNATIONAL (US) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | KDM4E 2471/4885MEN1 2531/4885ALDH1A1 1084/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | KDM4E 3895/4885MEN1 142/4885ALDH1A1 128/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | KDM4E 3895/4885MEN1 142/4885ALDH1A1 128/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | KDM4E 2471/4885MEN1 2531/4885ALDH1A1 1084/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | KDM4E 3061/4885MEN1 2007/4885ALDH1A1 1173/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | KDM4E 4822/4885MEN1 1978/4885ALDH1A1 100/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | KDM4E 1582/4885MEN1 3203/4885ALDH1A1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.